Healthcare >> Analyst Interviews >> October 2, 2018
Gene Therapy Companies with Better Clinical Data and Benefits Likely to Do Well
Difei Yang, Ph.D., serves as a Managing Director of Equity Research at Mizuho Securities USA LLC, Research Division. Dr. Yang is part of the Americas research team at the firm. Dr. Yang has been covering the biotech and pharma sector for nearly a decade, most recently serving as Managing Director at Aegis Capital. She has also served in senior equity analyst roles at Brean Capital, R.F. Lafferty, WallachBeth Capital and Auriga Global Investors. In addition to her research expertise, she has also held senior science, program management and business development roles within the pharmaceutical industry and has authored many granted U.S. patents and peer-reviewed scientific publications. She holds a Ph.D. in chemistry from the University of California Los Angeles as well as an MBA from Georgia State University and a B.S. in physics from Peking University, China. Profile
Word count: 2,141
TWST: Can you provide an overview of your coverage today?
Dr. Yang: I have a very broad coverage. I am looking for companies that have high